Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,190.00
Bid: 12,210.00
Ask: 12,214.00
Change: 162.00 (1.35%)
Spread: 4.00 (0.033%)
Open: 12,036.00
High: 12,214.00
Low: 12,024.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

24 Mar 2016 15:00

RNS Number : 2424T
AstraZeneca PLC
24 March 2016
 

Transaction by Persons Discharging Managerial Responsibilities

Disclosure Rule DTR 3.1.4

 

On 24 March 2016, the individuals listed below, who are all persons discharging managerial responsibilities, were granted awards over the Company's ordinary shares or American Depositary Shares (ADSs) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP), the AstraZeneca Performance Share Plan (AZPSP) and the AstraZeneca Investment Plan (AZIP). Two ADSs equal one ordinary share.

 

 

Name

Shares awarded under AZDBP

Shares awarded under AZPSP

Shares awarded under AZIP

Award price per share

 

Pascal Soriot

 

17,352

 

129,713

 

21,618

 

3923p

 

Marc Dunoyer

 

8,798

 

54,101

 

9,016

 

3923p

 

Sean Bohen

 

1,496

 

78,155

 

 

13,025

 

$28.19

 

Luke Miels

 

2,107

 

30,225

 

5,037

 

3923p

 

The AZDBP award represents the portion of each individual's annual bonus for 2015 that they are required to defer into shares. The shares are subject to a three-year holding period (24 March 2016 to 23 March 2019).

 

The AZPSP award is subject to a combination of performance measures focused on our scientific, commercial and financial performance assessed over a three-year performance period (1 January 2016 to 31 December 2018). The award will vest on the third anniversary of the date on which it was granted, except for awards to Executive Directors, which will be subject to a further two-year holding period before the award vests.

 

The AZIP award is subject to two performance hurdles relating to dividend and dividend cover over a four-year performance period (1 January 2016 to 31 December 2019). The award is subject to a four-year holding period, commencing at the end of the performance period.

 

Details of the performance measures that relate to the AZPSP and AZIP awards can be found in the Directors' Remuneration Report of the AstraZeneca Annual Report and Form 20-F Information 2015 which is available on the Company's website at www.astrazeneca-annualreports.com/2015/.

 

 

 

A C N Kemp

Company Secretary

24 March 2016

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUSASRNUAOUAR
Date   Source Headline
5th Sep 20177:00 amRNSDirectorate Change
1st Sep 20173:00 pmRNSTotal Voting Rights
29th Aug 20177:00 amRNSFaslodex gets US FDA OK for expanded use in breast
18th Aug 20177:00 amRNSLynparza gets broad FDA approval in ovarian cancer
16th Aug 20177:00 amRNSDirectorate Change
14th Aug 20174:30 pmRNSHolding(s) in Company
10th Aug 20171:30 pmRNSPublication of a Prospectus
2nd Aug 20177:00 amRNSAZ acalabrutinib submission accepted by US FDA
1st Aug 20173:00 pmRNSTotal Voting Rights
1st Aug 20177:00 amRNSBTD for AZ's acalabrutinib in mantle cell lymphoma
31st Jul 20177:00 amRNSImfinzi granted BTD by US FDA for Stage III nsclc
28th Jul 201711:00 amRNSDirector/PDMR Shareholding
27th Jul 20177:15 amRNSTagrisso significantly improves FLAURA
27th Jul 20177:11 amRNSAZ reports initial results from MYSTIC lung trial
27th Jul 20177:06 amRNSAZ & MERCK ESTABLISH STRATEGIC ONCOLOGY DEAL
27th Jul 20177:00 amRNSAstraZeneca PLC - H1 2017 Results
26th Jul 20174:46 pmRNSFaslodex receives EU approval for 1L breast cancer
21st Jul 20173:45 pmRNSHolding(s) in Company
3rd Jul 20172:59 pmRNSTotal Voting Rights
3rd Jul 20177:00 amRNSAZ COMPLETES SELOKEN AGREEMENT WITH RECORDATI
3rd Jul 20177:00 amRNSAZ COMPLETES ZOMIG DIVESTMENT WITH GRÜNENTHAL
23rd Jun 201712:46 pmRNSFaslodex CHMP positive opinion in 1L breast cancer
7th Jun 20177:13 amRNSAZ agreement with Grünenthal for rights to Zomig
6th Jun 20177:00 amRNSASTRAZENECA PRICES A $2BN BOND ISSUE
5th Jun 20177:00 amRNSLYNPARZA: SIGNIFICANT PFS IN BRCAm BREAST CANCER
1st Jun 20173:00 pmRNSBlock listing Interim Review
1st Jun 20173:00 pmRNSTotal Voting Rights
31st May 20177:00 amRNSDirectorate Change
24th May 20173:00 pmRNSDirector/PDMR Shareholding
23rd May 20177:00 amRNSBydureon EXSCEL trial meets T2D safety objective
22nd May 20177:00 amRNSAZ AGREEMENT WITH RECORDATI FOR SELOKEN IN EUROPE
16th May 20173:00 pmRNSDirector/PDMR Shareholding
12th May 20177:00 amRNSIMFINZI SIGNIFICANT PFS - UNRESECTABLE LUNG CANCER
10th May 20177:00 amRNSAZ updates on tralokinumab trial in severe asthma
2nd May 20172:00 pmRNSTotal Voting Rights
2nd May 20177:00 amRNSDURVALUMAB RECEIVES US FDA ACCELERATED APPROVAL
27th Apr 20175:30 pmRNSResult of AGM
27th Apr 20177:00 amRNSAstraZeneca: Q1 2017 Results
25th Apr 20171:30 pmRNSTAGRISSO RECEIVES FULL APPROVAL IN THE EU
12th Apr 20175:34 pmRNSNotification of Major Interest in Shares
3rd Apr 20173:00 pmRNSTotal Voting Rights
31st Mar 20177:01 amRNSTagrisso (osimertinib) receives FDA full approval
31st Mar 20177:00 amRNSAZ COMPLETES AGREEMENT WITH TERSERA THERAPEUTICS
28th Mar 20174:00 pmRNSDirector/PDMR Shareholding
27th Mar 20173:00 pmRNSDirector/PDMR Shareholding
17th Mar 20177:00 amRNSUS FDA issues CRL for ZS-9 in hyperkalaemia
16th Mar 201711:00 amRNSNotice of AGM
15th Mar 20177:00 amRNSLYNPARZA PFS IN BRCA OVARIAN MAINTENANCE THERAPY
8th Mar 20177:00 amRNSFiling of Form 20-F with SEC
7th Mar 20172:30 pmRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.